Age Related Macular Degeneration - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：268頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Age Related Macular Degeneration - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Age Related Macular Degeneration - Pipeline Review, H1 2014’, provides an overview of the Age Related Macular Degeneration’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Age Related Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Age Related Macular Degeneration and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Age Related Macular Degeneration and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Age Related Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Age Related Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Age Related Macular Degeneration
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Age Related Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Age Related Macular Degeneration - Pipeline Review, H1 2014’, provides an overview of the Age Related Macular Degeneration’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Age Related Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Age Related Macular Degeneration and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Age Related Macular Degeneration and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Age Related Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Age Related Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Age Related Macular Degeneration
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Age Related Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Age Related Macular Degeneration Overview 11
Therapeutics Development 12
Pipeline Products for Age Related Macular Degeneration - Overview 12
Pipeline Products for Age Related Macular Degeneration - Comparative Analysis 13
Age Related Macular Degeneration - Therapeutics under Development by Companies 14
Age Related Macular Degeneration - Therapeutics under Investigation by Universities/Institutes 20
Age Related Macular Degeneration - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Age Related Macular Degeneration - Products under Development by Companies 26
Age Related Macular Degeneration - Products under Investigation by Universities/Institutes 30
Age Related Macular Degeneration - Companies Involved in Therapeutics Development 31
Alcon, Inc. 31
Genzyme Corporation 32
F. Hoffmann-La Roche Ltd. 33
Allergan, Inc. 34
Shionogi & Co., Ltd. 35
GlaxoSmithKline plc 36
Dainippon Sumitomo Pharma Co., Ltd. 37
RetinaPharma Technologies, Inc. 38
Jeil Pharmaceutical Co., Ltd. 39
Merz Pharma GmbH & Co. KgaA 40
iCo Therapeutics Inc. 41
Mesoblast Limited 42
BioDiem Ltd 43
ReGenX Biosciences, LLC 44
OXiGENE, Inc. 45
NeoStem, Inc. 46
Progen Pharmaceuticals Limited 47
Handok Inc. 48
HanAll Biopharma Co., Ltd. 49
e-Therapeutics plc 50
R-Tech Ueno, Ltd. 51
Paloma Pharmaceuticals, Inc. 52
Digna Biotech, S.L. 53
StemCells, Inc. 54
Ora Bio Ltd. 55
Foamix Ltd. 56
Acucela Inc. 57
BioMAS Ltd. 58
Neovacs SA 59
Wellstat Ophthalmics Corporation 60
OcuCure Therapeutics, Inc. 61
Gene Signal International SA 62
Promedior, Inc. 63
Orphagen Pharmaceuticals, Inc. 64
Grupo Ferrer Internacional, S.A. 65
Intellect Neurosciences, Inc. 66
FirstString Research, Inc. 67
Stemedica Cell Technologies, Inc. 68
Cellceutix Corporation 69
Sirnaomics, Inc. 70
Resolvyx Pharmaceuticals, Inc 71
TRACON Pharmaceuticals, Inc. 72
AngioGenex, Inc. 73
SelectX Pharmaceuticals, Inc. 74
California Stem Cell, Inc. 75
Neumedicines Inc. 76
Varinel, Inc. 77
Aprogen, Inc. 78
Alkeus Pharmaceuticals, Inc. 79
X-BODY BioSciences, Inc. 80
Clanotech AB 81
Valens Therapeutics, Inc. 82
Allinky Biopharma 83
Neuroptis Biotech 84
AbbVie Inc. 85
AlphaMab Co., Ltd 86
Huabo Biopharm Co., Ltd. 87
Age Related Macular Degeneration - Therapeutics Assessment 88
Assessment by Monotherapy Products 88
Assessment by Target 89
Assessment by Mechanism of Action 93
Assessment by Route of Administration 97
Assessment by Molecule Type 100
Drug Profiles 103
KH-902 - Drug Profile 103
AS-101 - Drug Profile 105
fosbretabulin tromethamine - Drug Profile 107
pazopanib hydrochloride - Drug Profile 111
ORA-102 - Drug Profile 115
Allogeneic Mesenchymal Precursor Cells For Macular Degeneration - Drug Profile 116
S-646240 - Drug Profile 117
Human Neural Stem Cells - Drug Profile 118
sirolimus - Drug Profile 120
AVA-101 - Drug Profile 122
Induced Pluripotent Stem Cells - Drug Profile 124
volociximab - Drug Profile 126
ranibizumab - Drug Profile 130
PG-11047 - Drug Profile 133
bertilimumab - Drug Profile 135
GZ-402663 - Drug Profile 137
OC-10X - Drug Profile 138
aganirsen - Drug Profile 139
P-529 - Drug Profile 141
Peptide Vaccine - Drug Profile 143
ALK-001 - Drug Profile 144
MRZ-99030 - Drug Profile 145
CLG-561 - Drug Profile 146
PMX-20005 - Drug Profile 147
P-17 - Drug Profile 148
disitertide - Drug Profile 149
Drugs to Inhibit Tyrosine Kinase for AMD - Drug Profile 151
ETX-6201 - Drug Profile 152
VEGF Kinoid - Drug Profile 153
RX-20001 - Drug Profile 154
VAR-10200 - Drug Profile 155
TRC-105 - Drug Profile 156
HL-036 - Drug Profile 158
INN-01 - Drug Profile 159
fosbretabulin tromethamine - Drug Profile 160
BDM-E - Drug Profile 164
RTU-007 - Drug Profile 166
Retinylamine - Drug Profile 167
Gene Therapy For Age Related Macular Degeneration - Drug Profile 168
CIGB-166 - Drug Profile 169
NMIL-121 - Drug Profile 170
PRM-167 - Drug Profile 172
AGX-51 - Drug Profile 174
Drug For Ocular Diseases - Drug Profile 175
STP-601 - Drug Profile 176
Stem Cell Therapy For Macular Degeneration And Glaucoma - Drug Profile 177
AP-202 - Drug Profile 178
Lycium Anti-Angiogenic Proteoglycan - Drug Profile 179
Drug For Age-Related Macular Degeneration And Diabetic Retinopathy - Drug Profile 180
IN-N01-OX2 - Drug Profile 181
Anti-Angiogenic Compounds - Drug Profile 182
Cell Migration Inhibitors - Drug Profile 183
Small Molecules to Inhibit MMP - Drug Profile 184
Small Molecules For Age-Related Macular Degeneration - Drug Profile 185
Retinal Pigment Epithelial Progenitor Cells - Drug Profile 186
Small Molecules for AMD - Drug Profile 187
Asialo Triantennary Glycan - Drug Profile 188
Small Molecule For Age Related Macular Degeneration - Drug Profile 189
XB-2202 - Drug Profile 190
HMR-59 - Drug Profile 191
Stem Cell Therapy For Parkinson Disease And Age-related Macular Degeneration - Drug Profile 192
FIB-111 - Drug Profile 193
Drug For Age-Related Macular Degeneration - Drug Profile 194
MicroRNA-204 Mimic - Drug Profile 195
MicroRNA-211 Mimic - Drug Profile 197
ET-004 - Drug Profile 198
C16Y Peptide - Drug Profile 199
Vaccinia Virus Complement Control Protein - Drug Profile 200
CLT-28643 - Drug Profile 201
HB-002.1 - Drug Profile 202
Antibody for Age-Related Macular Degeneration - Drug Profile 203
Three-Dimensional (3D) Retinal Tissue - Drug Profile 205
ETX-6991 - Drug Profile 206
AIK-3 - Drug Profile 207
Embryonic Stem Cells for Age Related Macular Degeneration - Drug Profile 208
Neuregulins - Drug Profile 209
Small Molecules for CNS Disorders and Ophthalmology - Drug Profile 210
KN-014 - Drug Profile 211
PRCN-408 - Drug Profile 212
HL-5501 - Drug Profile 213
NOP-4 - Drug Profile 214
RPE Cells for Ophthalmic Disorders - Drug Profile 215
Small Molecules Targeting Nuclear Receptors for AMD - Drug Profile 216
INV-88 - Drug Profile 217
Small Molecules to Inhibit HTRA1 for AMD - Drug Profile 218
AVT-101 - Drug Profile 219
minocycline Gel - Drug Profile 220
Age Related Macular Degeneration - Recent Pipeline Updates 221
Age Related Macular Degeneration - Dormant Projects 250
Age Related Macular Degeneration - Discontinued Products 254
Age Related Macular Degeneration - Product Development Milestones 255
Featured News & Press Releases 255
Appendix 261
Methodology 261
Coverage 261
Secondary Research 261
Primary Research 261
Expert Panel Validation 261
Contact Us 262
Disclaimer 262
List of Tables
Number of Products under Development for Age Related Macular Degeneration, H1 2014 18
Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 21
Number of Products under Development by Companies, H1 2014 (Contd..1) 22
Number of Products under Development by Companies, H1 2014 (Contd..2) 23
Number of Products under Development by Companies, H1 2014 (Contd..3) 24
Number of Products under Development by Companies, H1 2014 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H1 2014 27
Comparative Analysis by Late Stage Development, H1 2014 28
Comparative Analysis by Clinical Stage Development, H1 2014 29
Comparative Analysis by Early Stage Development, H1 2014 30
Comparative Analysis by Unknown Stage Development, H1 2014 31
Products under Development by Companies, H1 2014 32
Products under Development by Companies, H1 2014 (Contd..1) 33
Products under Development by Companies, H1 2014 (Contd..2) 34
Products under Development by Companies, H1 2014 (Contd..3) 35
Products under Investigation by Universities/Institutes, H1 2014 36
Age Related Macular Degeneration - Pipeline by Alcon, Inc., H1 2014 37
Age Related Macular Degeneration - Pipeline by Genzyme Corporation, H1 2014 38
Age Related Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 39
Age Related Macular Degeneration - Pipeline by Allergan, Inc., H1 2014 40
Age Related Macular Degeneration - Pipeline by Shionogi & Co., Ltd., H1 2014 41
Age Related Macular Degeneration - Pipeline by GlaxoSmithKline plc, H1 2014 42
Age Related Macular Degeneration - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 43
Age Related Macular Degeneration - Pipeline by RetinaPharma Technologies, Inc., H1 2014 44
Age Related Macular Degeneration - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2014 45
Age Related Macular Degeneration - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2014 46
Age Related Macular Degeneration - Pipeline by iCo Therapeutics Inc., H1 2014 47
Age Related Macular Degeneration - Pipeline by Mesoblast Limited, H1 2014 48
Age Related Macular Degeneration - Pipeline by BioDiem Ltd, H1 2014 49
Age Related Macular Degeneration - Pipeline by ReGenX Biosciences, LLC, H1 2014 50
Age Related Macular Degeneration - Pipeline by OXiGENE, Inc., H1 2014 51
Age Related Macular Degeneration - Pipeline by NeoStem, Inc., H1 2014 52
Age Related Macular Degeneration - Pipeline by Progen Pharmaceuticals Limited, H1 2014 53
Age Related Macular Degeneration - Pipeline by Handok Inc., H1 2014 54
Age Related Macular Degeneration - Pipeline by HanAll Biopharma Co., Ltd., H1 2014 55
Age Related Macular Degeneration - Pipeline by e-Therapeutics plc, H1 2014 56
Age Related Macular Degeneration - Pipeline by R-Tech Ueno, Ltd., H1 2014 57
Age Related Macular Degeneration - Pipeline by Paloma Pharmaceuticals, Inc., H1 2014 58
Age Related Macular Degeneration - Pipeline by Digna Biotech, S.L., H1 2014 59
Age Related Macular Degeneration - Pipeline by StemCells, Inc., H1 2014 60
Age Related Macular Degeneration - Pipeline by Ora Bio Ltd., H1 2014 61
Age Related Macular Degeneration - Pipeline by Foamix Ltd., H1 2014 62
Age Related Macular Degeneration - Pipeline by Acucela Inc., H1 2014 63
Age Related Macular Degeneration - Pipeline by BioMAS Ltd., H1 2014 64
Age Related Macular Degeneration - Pipeline by Neovacs SA, H1 2014 65
Age Related Macular Degeneration - Pipeline by Wellstat Ophthalmics Corporation, H1 2014 66
Age Related Macular Degeneration - Pipeline by OcuCure Therapeutics, Inc., H1 2014 67
Age Related Macular Degeneration - Pipeline by Gene Signal International SA, H1 2014 68
Age Related Macular Degeneration - Pipeline by Promedior, Inc., H1 2014 69
Age Related Macular Degeneration - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2014 70
Age Related Macular Degeneration - Pipeline by Grupo Ferrer Internacional, S.A., H1 2014 71
Age Related Macular Degeneration - Pipeline by Intellect Neurosciences, Inc., H1 2014 72
Age Related Macular Degeneration - Pipeline by FirstString Research, Inc., H1 2014 73
Age Related Macular Degeneration - Pipeline by Stemedica Cell Technologies, Inc., H1 2014 74
Age Related Macular Degeneration - Pipeline by Cellceutix Corporation, H1 2014 75
Age Related Macular Degeneration - Pipeline by Sirnaomics, Inc., H1 2014 76
Age Related Macular Degeneration - Pipeline by Resolvyx Pharmaceuticals, Inc, H1 2014 77
Age Related Macular Degeneration - Pipeline by TRACON Pharmaceuticals, Inc., H1 2014 78
Age Related Macular Degeneration - Pipeline by AngioGenex, Inc., H1 2014 79
Age Related Macular Degeneration - Pipeline by SelectX Pharmaceuticals, Inc., H1 2014 80
Age Related Macular Degeneration - Pipeline by California Stem Cell, Inc., H1 2014 81
Age Related Macular Degeneration - Pipeline by Neumedicines Inc., H1 2014 82
Age Related Macular Degeneration - Pipeline by Varinel, Inc., H1 2014 83
Age Related Macular Degeneration - Pipeline by Aprogen, Inc., H1 2014 84
Age Related Macular Degeneration - Pipeline by Alkeus Pharmaceuticals, Inc., H1 2014 85
Age Related Macular Degeneration - Pipeline by X-BODY BioSciences, Inc., H1 2014 86
Age Related Macular Degeneration - Pipeline by Clanotech AB, H1 2014 87
Age Related Macular Degeneration - Pipeline by Valens Therapeutics, Inc., H1 2014 88
Age Related Macular Degeneration - Pipeline by Allinky Biopharma, H1 2014 89
Age Related Macular Degeneration - Pipeline by Neuroptis Biotech, H1 2014 90
Age Related Macular Degeneration - Pipeline by AbbVie Inc., H1 2014 91
Age Related Macular Degeneration - Pipeline by AlphaMab Co., Ltd, H1 2014 92
Age Related Macular Degeneration - Pipeline by Huabo Biopharm Co., Ltd., H1 2014 93
Assessment by Monotherapy Products, H1 2014 94
Number of Products by Stage and Target, H1 2014 97
Number of Products by Stage and Mechanism of Action, H1 2014 101
Number of Products by Stage and Route of Administration, H1 2014 105
Number of Products by Stage and Molecule Type, H1 2014 108
Age Related Macular Degeneration Therapeutics - Recent Pipeline Updates, H1 2014 227
Age Related Macular Degeneration - Dormant Projects, H1 2014 256
Age Related Macular Degeneration - Dormant Projects (Contd..1), H1 2014 257
Age Related Macular Degeneration - Dormant Projects (Contd..2), H1 2014 258
Age Related Macular Degeneration - Dormant Projects (Contd..3), H1 2014 259
Age Related Macular Degeneration - Discontinued Products, H1 2014 260
List of Figures
Number of Products under Development for Age Related Macular Degeneration, H1 2014 18
Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 20
Number of Products under Investigation by Universities/Institutes, H1 2014 26
Comparative Analysis by Clinical Stage Development, H1 2014 29
Comparative Analysis by Early Stage Products, H1 2014 30
Assessment by Monotherapy Products, H1 2014 94
Number of Products by Top 10 Target, H1 2014 95
Number of Products by Stage and Top 10 Target, H1 2014 96
Number of Products by Top 10 Mechanism of Action, H1 2014 99
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 100
Number of Products by Top 10 Route of Administration, H1 2014 103
Number of Products by Stage and Top 10 Route of Administration, H1 2014 104
Number of Products by Top 10 Molecule Type, H1 2014 106
Number of Products by Stage and Top 10 Molecule Type, H1 2014 107
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Age Related Macular Degeneration Overview 11
Therapeutics Development 12
Pipeline Products for Age Related Macular Degeneration - Overview 12
Pipeline Products for Age Related Macular Degeneration - Comparative Analysis 13
Age Related Macular Degeneration - Therapeutics under Development by Companies 14
Age Related Macular Degeneration - Therapeutics under Investigation by Universities/Institutes 20
Age Related Macular Degeneration - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Age Related Macular Degeneration - Products under Development by Companies 26
Age Related Macular Degeneration - Products under Investigation by Universities/Institutes 30
Age Related Macular Degeneration - Companies Involved in Therapeutics Development 31
Alcon, Inc. 31
Genzyme Corporation 32
F. Hoffmann-La Roche Ltd. 33
Allergan, Inc. 34
Shionogi & Co., Ltd. 35
GlaxoSmithKline plc 36
Dainippon Sumitomo Pharma Co., Ltd. 37
RetinaPharma Technologies, Inc. 38
Jeil Pharmaceutical Co., Ltd. 39
Merz Pharma GmbH & Co. KgaA 40
iCo Therapeutics Inc. 41
Mesoblast Limited 42
BioDiem Ltd 43
ReGenX Biosciences, LLC 44
OXiGENE, Inc. 45
NeoStem, Inc. 46
Progen Pharmaceuticals Limited 47
Handok Inc. 48
HanAll Biopharma Co., Ltd. 49
e-Therapeutics plc 50
R-Tech Ueno, Ltd. 51
Paloma Pharmaceuticals, Inc. 52
Digna Biotech, S.L. 53
StemCells, Inc. 54
Ora Bio Ltd. 55
Foamix Ltd. 56
Acucela Inc. 57
BioMAS Ltd. 58
Neovacs SA 59
Wellstat Ophthalmics Corporation 60
OcuCure Therapeutics, Inc. 61
Gene Signal International SA 62
Promedior, Inc. 63
Orphagen Pharmaceuticals, Inc. 64
Grupo Ferrer Internacional, S.A. 65
Intellect Neurosciences, Inc. 66
FirstString Research, Inc. 67
Stemedica Cell Technologies, Inc. 68
Cellceutix Corporation 69
Sirnaomics, Inc. 70
Resolvyx Pharmaceuticals, Inc 71
TRACON Pharmaceuticals, Inc. 72
AngioGenex, Inc. 73
SelectX Pharmaceuticals, Inc. 74
California Stem Cell, Inc. 75
Neumedicines Inc. 76
Varinel, Inc. 77
Aprogen, Inc. 78
Alkeus Pharmaceuticals, Inc. 79
X-BODY BioSciences, Inc. 80
Clanotech AB 81
Valens Therapeutics, Inc. 82
Allinky Biopharma 83
Neuroptis Biotech 84
AbbVie Inc. 85
AlphaMab Co., Ltd 86
Huabo Biopharm Co., Ltd. 87
Age Related Macular Degeneration - Therapeutics Assessment 88
Assessment by Monotherapy Products 88
Assessment by Target 89
Assessment by Mechanism of Action 93
Assessment by Route of Administration 97
Assessment by Molecule Type 100
Drug Profiles 103
KH-902 - Drug Profile 103
AS-101 - Drug Profile 105
fosbretabulin tromethamine - Drug Profile 107
pazopanib hydrochloride - Drug Profile 111
ORA-102 - Drug Profile 115
Allogeneic Mesenchymal Precursor Cells For Macular Degeneration - Drug Profile 116
S-646240 - Drug Profile 117
Human Neural Stem Cells - Drug Profile 118
sirolimus - Drug Profile 120
AVA-101 - Drug Profile 122
Induced Pluripotent Stem Cells - Drug Profile 124
volociximab - Drug Profile 126
ranibizumab - Drug Profile 130
PG-11047 - Drug Profile 133
bertilimumab - Drug Profile 135
GZ-402663 - Drug Profile 137
OC-10X - Drug Profile 138
aganirsen - Drug Profile 139
P-529 - Drug Profile 141
Peptide Vaccine - Drug Profile 143
ALK-001 - Drug Profile 144
MRZ-99030 - Drug Profile 145
CLG-561 - Drug Profile 146
PMX-20005 - Drug Profile 147
P-17 - Drug Profile 148
disitertide - Drug Profile 149
Drugs to Inhibit Tyrosine Kinase for AMD - Drug Profile 151
ETX-6201 - Drug Profile 152
VEGF Kinoid - Drug Profile 153
RX-20001 - Drug Profile 154
VAR-10200 - Drug Profile 155
TRC-105 - Drug Profile 156
HL-036 - Drug Profile 158
INN-01 - Drug Profile 159
fosbretabulin tromethamine - Drug Profile 160
BDM-E - Drug Profile 164
RTU-007 - Drug Profile 166
Retinylamine - Drug Profile 167
Gene Therapy For Age Related Macular Degeneration - Drug Profile 168
CIGB-166 - Drug Profile 169
NMIL-121 - Drug Profile 170
PRM-167 - Drug Profile 172
AGX-51 - Drug Profile 174
Drug For Ocular Diseases - Drug Profile 175
STP-601 - Drug Profile 176
Stem Cell Therapy For Macular Degeneration And Glaucoma - Drug Profile 177
AP-202 - Drug Profile 178
Lycium Anti-Angiogenic Proteoglycan - Drug Profile 179
Drug For Age-Related Macular Degeneration And Diabetic Retinopathy - Drug Profile 180
IN-N01-OX2 - Drug Profile 181
Anti-Angiogenic Compounds - Drug Profile 182
Cell Migration Inhibitors - Drug Profile 183
Small Molecules to Inhibit MMP - Drug Profile 184
Small Molecules For Age-Related Macular Degeneration - Drug Profile 185
Retinal Pigment Epithelial Progenitor Cells - Drug Profile 186
Small Molecules for AMD - Drug Profile 187
Asialo Triantennary Glycan - Drug Profile 188
Small Molecule For Age Related Macular Degeneration - Drug Profile 189
XB-2202 - Drug Profile 190
HMR-59 - Drug Profile 191
Stem Cell Therapy For Parkinson Disease And Age-related Macular Degeneration - Drug Profile 192
FIB-111 - Drug Profile 193
Drug For Age-Related Macular Degeneration - Drug Profile 194
MicroRNA-204 Mimic - Drug Profile 195
MicroRNA-211 Mimic - Drug Profile 197
ET-004 - Drug Profile 198
C16Y Peptide - Drug Profile 199
Vaccinia Virus Complement Control Protein - Drug Profile 200
CLT-28643 - Drug Profile 201
HB-002.1 - Drug Profile 202
Antibody for Age-Related Macular Degeneration - Drug Profile 203
Three-Dimensional (3D) Retinal Tissue - Drug Profile 205
ETX-6991 - Drug Profile 206
AIK-3 - Drug Profile 207
Embryonic Stem Cells for Age Related Macular Degeneration - Drug Profile 208
Neuregulins - Drug Profile 209
Small Molecules for CNS Disorders and Ophthalmology - Drug Profile 210
KN-014 - Drug Profile 211
PRCN-408 - Drug Profile 212
HL-5501 - Drug Profile 213
NOP-4 - Drug Profile 214
RPE Cells for Ophthalmic Disorders - Drug Profile 215
Small Molecules Targeting Nuclear Receptors for AMD - Drug Profile 216
INV-88 - Drug Profile 217
Small Molecules to Inhibit HTRA1 for AMD - Drug Profile 218
AVT-101 - Drug Profile 219
minocycline Gel - Drug Profile 220
Age Related Macular Degeneration - Recent Pipeline Updates 221
Age Related Macular Degeneration - Dormant Projects 250
Age Related Macular Degeneration - Discontinued Products 254
Age Related Macular Degeneration - Product Development Milestones 255
Featured News & Press Releases 255
Appendix 261
Methodology 261
Coverage 261
Secondary Research 261
Primary Research 261
Expert Panel Validation 261
Contact Us 262
Disclaimer 262
List of Tables
Number of Products under Development for Age Related Macular Degeneration, H1 2014 18
Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 21
Number of Products under Development by Companies, H1 2014 (Contd..1) 22
Number of Products under Development by Companies, H1 2014 (Contd..2) 23
Number of Products under Development by Companies, H1 2014 (Contd..3) 24
Number of Products under Development by Companies, H1 2014 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H1 2014 27
Comparative Analysis by Late Stage Development, H1 2014 28
Comparative Analysis by Clinical Stage Development, H1 2014 29
Comparative Analysis by Early Stage Development, H1 2014 30
Comparative Analysis by Unknown Stage Development, H1 2014 31
Products under Development by Companies, H1 2014 32
Products under Development by Companies, H1 2014 (Contd..1) 33
Products under Development by Companies, H1 2014 (Contd..2) 34
Products under Development by Companies, H1 2014 (Contd..3) 35
Products under Investigation by Universities/Institutes, H1 2014 36
Age Related Macular Degeneration - Pipeline by Alcon, Inc., H1 2014 37
Age Related Macular Degeneration - Pipeline by Genzyme Corporation, H1 2014 38
Age Related Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 39
Age Related Macular Degeneration - Pipeline by Allergan, Inc., H1 2014 40
Age Related Macular Degeneration - Pipeline by Shionogi & Co., Ltd., H1 2014 41
Age Related Macular Degeneration - Pipeline by GlaxoSmithKline plc, H1 2014 42
Age Related Macular Degeneration - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 43
Age Related Macular Degeneration - Pipeline by RetinaPharma Technologies, Inc., H1 2014 44
Age Related Macular Degeneration - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2014 45
Age Related Macular Degeneration - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2014 46
Age Related Macular Degeneration - Pipeline by iCo Therapeutics Inc., H1 2014 47
Age Related Macular Degeneration - Pipeline by Mesoblast Limited, H1 2014 48
Age Related Macular Degeneration - Pipeline by BioDiem Ltd, H1 2014 49
Age Related Macular Degeneration - Pipeline by ReGenX Biosciences, LLC, H1 2014 50
Age Related Macular Degeneration - Pipeline by OXiGENE, Inc., H1 2014 51
Age Related Macular Degeneration - Pipeline by NeoStem, Inc., H1 2014 52
Age Related Macular Degeneration - Pipeline by Progen Pharmaceuticals Limited, H1 2014 53
Age Related Macular Degeneration - Pipeline by Handok Inc., H1 2014 54
Age Related Macular Degeneration - Pipeline by HanAll Biopharma Co., Ltd., H1 2014 55
Age Related Macular Degeneration - Pipeline by e-Therapeutics plc, H1 2014 56
Age Related Macular Degeneration - Pipeline by R-Tech Ueno, Ltd., H1 2014 57
Age Related Macular Degeneration - Pipeline by Paloma Pharmaceuticals, Inc., H1 2014 58
Age Related Macular Degeneration - Pipeline by Digna Biotech, S.L., H1 2014 59
Age Related Macular Degeneration - Pipeline by StemCells, Inc., H1 2014 60
Age Related Macular Degeneration - Pipeline by Ora Bio Ltd., H1 2014 61
Age Related Macular Degeneration - Pipeline by Foamix Ltd., H1 2014 62
Age Related Macular Degeneration - Pipeline by Acucela Inc., H1 2014 63
Age Related Macular Degeneration - Pipeline by BioMAS Ltd., H1 2014 64
Age Related Macular Degeneration - Pipeline by Neovacs SA, H1 2014 65
Age Related Macular Degeneration - Pipeline by Wellstat Ophthalmics Corporation, H1 2014 66
Age Related Macular Degeneration - Pipeline by OcuCure Therapeutics, Inc., H1 2014 67
Age Related Macular Degeneration - Pipeline by Gene Signal International SA, H1 2014 68
Age Related Macular Degeneration - Pipeline by Promedior, Inc., H1 2014 69
Age Related Macular Degeneration - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2014 70
Age Related Macular Degeneration - Pipeline by Grupo Ferrer Internacional, S.A., H1 2014 71
Age Related Macular Degeneration - Pipeline by Intellect Neurosciences, Inc., H1 2014 72
Age Related Macular Degeneration - Pipeline by FirstString Research, Inc., H1 2014 73
Age Related Macular Degeneration - Pipeline by Stemedica Cell Technologies, Inc., H1 2014 74
Age Related Macular Degeneration - Pipeline by Cellceutix Corporation, H1 2014 75
Age Related Macular Degeneration - Pipeline by Sirnaomics, Inc., H1 2014 76
Age Related Macular Degeneration - Pipeline by Resolvyx Pharmaceuticals, Inc, H1 2014 77
Age Related Macular Degeneration - Pipeline by TRACON Pharmaceuticals, Inc., H1 2014 78
Age Related Macular Degeneration - Pipeline by AngioGenex, Inc., H1 2014 79
Age Related Macular Degeneration - Pipeline by SelectX Pharmaceuticals, Inc., H1 2014 80
Age Related Macular Degeneration - Pipeline by California Stem Cell, Inc., H1 2014 81
Age Related Macular Degeneration - Pipeline by Neumedicines Inc., H1 2014 82
Age Related Macular Degeneration - Pipeline by Varinel, Inc., H1 2014 83
Age Related Macular Degeneration - Pipeline by Aprogen, Inc., H1 2014 84
Age Related Macular Degeneration - Pipeline by Alkeus Pharmaceuticals, Inc., H1 2014 85
Age Related Macular Degeneration - Pipeline by X-BODY BioSciences, Inc., H1 2014 86
Age Related Macular Degeneration - Pipeline by Clanotech AB, H1 2014 87
Age Related Macular Degeneration - Pipeline by Valens Therapeutics, Inc., H1 2014 88
Age Related Macular Degeneration - Pipeline by Allinky Biopharma, H1 2014 89
Age Related Macular Degeneration - Pipeline by Neuroptis Biotech, H1 2014 90
Age Related Macular Degeneration - Pipeline by AbbVie Inc., H1 2014 91
Age Related Macular Degeneration - Pipeline by AlphaMab Co., Ltd, H1 2014 92
Age Related Macular Degeneration - Pipeline by Huabo Biopharm Co., Ltd., H1 2014 93
Assessment by Monotherapy Products, H1 2014 94
Number of Products by Stage and Target, H1 2014 97
Number of Products by Stage and Mechanism of Action, H1 2014 101
Number of Products by Stage and Route of Administration, H1 2014 105
Number of Products by Stage and Molecule Type, H1 2014 108
Age Related Macular Degeneration Therapeutics - Recent Pipeline Updates, H1 2014 227
Age Related Macular Degeneration - Dormant Projects, H1 2014 256
Age Related Macular Degeneration - Dormant Projects (Contd..1), H1 2014 257
Age Related Macular Degeneration - Dormant Projects (Contd..2), H1 2014 258
Age Related Macular Degeneration - Dormant Projects (Contd..3), H1 2014 259
Age Related Macular Degeneration - Discontinued Products, H1 2014 260
List of Figures
Number of Products under Development for Age Related Macular Degeneration, H1 2014 18
Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 20
Number of Products under Investigation by Universities/Institutes, H1 2014 26
Comparative Analysis by Clinical Stage Development, H1 2014 29
Comparative Analysis by Early Stage Products, H1 2014 30
Assessment by Monotherapy Products, H1 2014 94
Number of Products by Top 10 Target, H1 2014 95
Number of Products by Stage and Top 10 Target, H1 2014 96
Number of Products by Top 10 Mechanism of Action, H1 2014 99
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 100
Number of Products by Top 10 Route of Administration, H1 2014 103
Number of Products by Stage and Top 10 Route of Administration, H1 2014 104
Number of Products by Top 10 Molecule Type, H1 2014 106
Number of Products by Stage and Top 10 Molecule Type, H1 2014 107
